-
公开(公告)号：US11078518B2
公开(公告)日：2021-08-03
申请号：US14431425
申请日：2013-09-26
发明人： Tetsuhiro Soeda , Takehisa Kitazawa , Midori Shima
摘要： Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.
-
公开(公告)号：US20190248921A1
公开(公告)日：2019-08-15
申请号：US16391848
申请日：2019-04-23
IPC分类号： C07K16/40 , A61K45/06 , A61K39/395
CPC分类号： C07K16/40 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/76 , A61K2300/00
摘要： The present inventors have completed the present invention by finding that an excellent anticoagulation inhibitory effect is obtained by the administration of an agent inhibiting the activation of protein C.
-
公开(公告)号：US20210380717A1
公开(公告)日：2021-12-09
申请号：US17389534
申请日：2021-07-30
摘要： The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
-
公开(公告)号：US20210107995A1
公开(公告)日：2021-04-15
申请号：US17130736
申请日：2020-12-22
摘要： The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
-
公开(公告)号：US20200223940A1
公开(公告)日：2020-07-16
申请号：US16099341
申请日：2018-09-27
发明人： Yuri Teranishi , Kazuki Kato , Hikaru Koga , Tomoyuki Igawa , Kazuki Yamaguchi , Tetsuhiro Soeda
IPC分类号： C07K16/36
摘要： Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.
-
公开(公告)号：US20140370018A1
公开(公告)日：2014-12-18
申请号：US14019117
申请日：2013-09-05
发明人： Tomoyuki Igawa , Zenjiro Sampei , Tetsuo Kojima , Tetsuhiro Soeda , Atsushi Muto , Takehisa Kitazawa , Yukiko Nishida , Chifumi Imai , Tsukasa Suzuki , Kazutaka Yoshihashi
IPC分类号： C07K16/40
CPC分类号： C07K16/40 , C07K16/36 , C07K2317/31 , C07K2317/51 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/94
摘要： Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.
摘要翻译： 各种双特异性抗体特异性结合血液凝固因子IX /活化血液凝固因子IX和血液凝固因子X，并功能取代血液凝固因子VIII的辅因子功能，即促进凝血因子X活化的功能 活化血液凝固因子IX。 从这些抗体中，成功发现了具有高功能取代凝血因子VIII活性的多特异性抗原结合分子。
-
公开(公告)号：US20140037632A1
公开(公告)日：2014-02-06
申请号：US14019712
申请日：2013-09-06
发明人： Tomoyuki Igawa , Zenjiro Sampei , Tetsuo Kojima , Tetsuhiro Soeda , Atsushi Muto , Takehisa Kitazawa , Yukiko Nishida , Chifumi Imai , Tsukasa Suzuki , Kazutaka Yoshihashi
IPC分类号： C07K16/36
CPC分类号： C07K16/40 , C07K16/36 , C07K2317/31 , C07K2317/51 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/94
摘要： Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.
-
公开(公告)号：US20240190997A1
公开(公告)日：2024-06-13
申请号：US18586698
申请日：2024-02-26
CPC分类号： C07K16/36 , C07K16/00 , C07K16/40 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/622 , C07K2317/75
摘要： The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
-
9.发明公开公开(公告)号：US20240059795A1
公开(公告)日：2024-02-22
申请号：US18495861
申请日：2023-10-27
发明人： Tomoyuki Igawa , Zenjiro Sampei , Tetsuo Kojima , Tetsuhiro Soeda , Atsushi Muto , Takehisa Kitazawa , Yukiko Nishida , Chifumi Imai , Tsukasa Suzuki , Kazutaka Yoshihashi
CPC分类号： C07K16/40 , C07K16/36 , C07K2317/31 , C07K2317/75 , C07K2317/76 , C07K2317/56 , C07K2317/565 , C07K2317/94 , C07K2317/51
摘要： Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.
-
公开(公告)号：US20200277402A1
公开(公告)日：2020-09-03
申请号：US16825513
申请日：2020-03-20
摘要： The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.019 秒)
